Highview Capital Management’s Amgen AMGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.44M Buy
3,963
+103
+3% +$35.3K 0.41% 65
2026
Q1
$1.36M Buy
+3,860
New +$1.38M 0.49% 62
2023
Q2
Sell
-1,167
Closed -$282K 96
2023
Q1
$282K Hold
1,167
0.16% 81
2022
Q4
$307K Hold
1,167
0.19% 87
2022
Q3
$263K Sell
1,167
-186
-14% -$45.1K 0.2% 86
2022
Q2
$329K Buy
1,353
+17
+1% +$4.17K 0.25% 76
2022
Q1
$323K Buy
1,336
+169
+14% +$38.8K 0.21% 94
2021
Q4
$263K Buy
+1,167
New +$246K 0.17% 94

Other funds holding AMGN

Highview Capital Management's AMGN Position: Q2 2026 in Review

Highview Capital Management increased its Amgen (AMGN) stake by 2.7% in Q2 2026, buying an estimated $35.3K and bringing the position to 3,963 shares worth $1.44M. The position accounts for 0.41% of the portfolio, ranked #65.

Highview Capital Management first reported a position in AMGN in Q4 2021 and has held it in 8 quarters since. 3,139 funds tracked by Wall St. Rank hold AMGN as of Q2 2026.

  • Highview Capital Management held 3,963 shares of Amgen worth $1.44M as of Q2 2026.
  • Highview Capital Management bought 103 Amgen shares in Q2 2026, an estimated $35.3K.
  • Amgen made up 0.41% of Highview Capital Management's portfolio in Q2 2026, its #65 holding.
  • Highview Capital Management first reported a position in Amgen in Q4 2021 and has held it in 8 quarters since.
  • 3,139 funds tracked by Wall St. Rank held Amgen as of Q2 2026.

Based on Highview Capital Management's 13F filing for Q2 2026, filed 11 Aug 2026.